Finzati - Logo
PCRX logo

Pacira BioSciences, Inc.

PCRX • Drug Manufacturers - Specialty & Generic
$26.35
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$1.07B
Growth
-2.8%
Cash Flow
5/5
Trend
Stable
Evidence
Positive revenue growth · 7.4%Positive free cash flow · 3.07Consistent free cash flow · 5/5Manageable debt level · 0.66Healthy liquidity · 4.54
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 1:02 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$26.35
Change0.00%
Shares Out40.60M
Market Cap$1.07B
Enterprise Value$1.18B
52W Range18.80 - 27.64
Beta0.27
P/E73.09
P/S1.43
P/B1.59
P/FCF5.96
EV/Sales1.58

Investment DNA

How strong this company looks for long-term investors

69
out of 100
Business Quality
Margins, moat, returns
35/100
Financial Strength
Debt, cash, stability
73/100
Growth Potential
Revenue and expansion
89/100
Price Attractiveness
Cheap or expensive today
74/100
Why this score▼
Positive revenue growth · 7.4%Positive free cash flow · 3.07Consistent free cash flow · 5/5Manageable debt level · 0.66Healthy liquidity · 4.54Expensive earnings multiple · 163.97

Analyst view

Analyst sentiment and price target

PCRX
Analyst sentiment
Based on 36 analyst votes · 2026-09-04
65/100
Neutral
Bullish
15
Hold
17
Bearish
4
Price Target
2026-08-06
Low
$25.00
Mean
$28.50
Median
$28.50
High
$32.00

Company Overview

IPO: 2/3/2011
Industry: Drug Manufacturers - Specialty & Generic
P/B i: 1.59
Debt / Equity i: 0.66
Operating Margin: 4.58%
Net Margin: 0.97%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.66
Current Ratio: 4.54
Quick Ratio: 3.28
Status: Good

Insider Transactions

Recent executive and insider activity

RIKER LAUREN
Transaction: 06/11/2026
SELL
Change
-6,115
Price
$23.50
Filing
06/12/2026
Type
SELL
Brege Laura
Transaction: 06/10/2026
BUY
Change
+10,891
Price
$23.42
Filing
06/12/2026
Type
BUY
Brege Laura
Transaction: 06/10/2026
BUY
Change
+6,405
Price
Not reported
Filing
06/12/2026
Type
BUY